APTX - Aptinyx Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.6500
-0.0600 (-1.62%)
At close: 4:00PM EDT

3.6500 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close3.7100
Open3.7300
Bid3.6100 x 900
Ask3.6800 x 800
Day's Range3.5300 - 3.7300
52 Week Range3.4500 - 32.2500
Volume228,900
Avg. Volume388,709
Market Cap122.502M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.6380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today highlighted detailed analysis of the recently completed Phase 2 study of its novel NMDA receptor modulator, NYX-2925, in patients with painful diabetic peripheral neuropathy (DPN). “In patients who experience chronic pain, there can be an evolution in the disorder over time as pain processing shifts from peripheral to central sensitization. This central manifestation of pain becomes more prominent in patients who have had chronic pain for a long time and most therapies offer little relief for these patients.

  • GlobeNewswire18 days ago

    Aptinyx to Present at 18th Annual Needham Healthcare Conference

    EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 18th Annual Needham Healthcare Conference. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

  • GlobeNewswire20 days ago

    Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical data on its novel NMDA receptor modulator, NYX-458, demonstrating reversal of cognitive deficits in a non-human primate model of Parkinson’s disease. “With up to half of all people with Parkinson’s disease experiencing cognitive impairment and very few therapeutic options addressing these cognitive deficits, the unmet need in Parkinson’s cognitive impairment is immense,” said Norbert Riedel, Ph.D., president and chief executive officer at Aptinyx.

  • GlobeNewswire26 days ago

    Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting

    EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detailed results from a recently completed Phase 2 study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). The poster presentation will take place at the American Pain Society Scientific Meeting in Milwaukee, Wisconsin on April 4, 2019. “While we announced in January that the study did not meet the primary endpoint in the total study population, the findings from the detailed analysis provide a strong scientific foundation for advancing the development of NYX-2925 for the treatment of chronic pain,” said Norbert Riedel, president and chief executive officer of Aptinyx.

  • All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy
    Zacks26 days ago

    All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy

    Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswirelast month

    Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations highlighting preclinical data on its novel NMDA receptor modulator, NYX-458, at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases in Lisbon, Portugal. “We are excited to present these data, demonstrating the striking effects that NYX-458 has on cognitive impairment in a highly translatable non-human primate model of Parkinson’s disease,” said Cassia Cearley, Ph.D., vice president of research at Aptinyx.

  • GlobeNewswirelast month

    Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

    Completed Phase 2 study of NYX-2925 in painful DPN -- did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant.

  • GlobeNewswirelast month

    Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, March 21st, 2019, at 8:00 A.M. ET to report fourth quarter and full year 2018 financial results and to discuss recent business updates. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.

  • GlobeNewswire2 months ago

    Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the Cowen and Company 39th Annual Health Care Conference. The presentation will take place at 9:20 a.m. ET on March 13, 2019 at The Boston Marriott Copley Place in Boston, MA. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

  • GlobeNewswire2 months ago

    Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference. The fireside chat will take place at 9:00 a.m. ET on March 1, 2019 at the Lotte New York Palace in New York City. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

  • GlobeNewswire2 months ago

    Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has dosed the first patient in a Phase 2 study of NYX-783 for the treatment of Post-Traumatic Stress Disorder (PTSD). NYX-783 is a novel NMDA receptor modulator and its development in PTSD has been granted Fast Track designation by the U.S. Food and Drug Administration. “PTSD is a devastating condition that affects millions of people for whom the existing therapeutic options offer inadequate symptom relief,” said Norbert Riedel, Ph.D., president and CEO of Aptinyx.

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...

  • TheStreet.com3 months ago

    Biotech Play Aptinyx Tanks After Drug Trial Fails

    Evanston, IL-based biopharma company Aptinyx Inc. is tanking Wednesday after the phase 2 trial for the company's diabetic peripheral neuropathy treatment did not meet its primary endpoint. The company said that the trial did not demonstrate statistically significant separation in outcomes when compared to a placebo in the double-blind controlled study of 300 patients suffering from the disease.

  • Why Ford Motor, Snap, and Aptinyx Slumped Today
    Motley Fool3 months ago

    Why Ford Motor, Snap, and Aptinyx Slumped Today

    Despite a good day for markets, these stocks missed out.

  • Here's Why Aptinyx Got Crushed Today
    Motley Fool3 months ago

    Here's Why Aptinyx Got Crushed Today

    The company reported results for an important phase 2 trial.

  • GlobeNewswire3 months ago

    Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

    NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects.

  • GlobeNewswire4 months ago

    Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference

    EVANSTON, Ill., Jan. 02, 2019 -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and.

  • Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)?
    Simply Wall St.4 months ago

    Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...

  • GlobeNewswire4 months ago

    Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced two upcoming poster presentations highlighting preclinical data on its novel NMDA receptor (NMDAr) modulator, NYX-2925, at the American College of Neuropsychopharmacology’s Annual Meeting in Hollywood, Florida. “We are encouraged by the preclinical effects we see with NYX-2925 on synaptic plasticity and sleep architecture, both of which are known to be NMDA receptor mediated,” said Joseph Moskal, Ph.D., chief scientific officer at Aptinyx.

  • GlobeNewswire5 months ago

    Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

    EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference. The fireside chat will take place at 10:00 a.m. ET on December 12, 2018 at the Mandarin Oriental New York Hotel in New York City. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com.

  • GlobeNewswire5 months ago

    Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study receive daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

  • GlobeNewswire5 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights

    Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in.

  • GlobeNewswire5 months ago

    Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans

    Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that exploratory clinical studies of its novel NMDA receptor (NMDAr) modulator, NYX-2925, provide the first evidence that oral dosing of the product candidate induces pharmacodynamic activities in humans that are understood to be NMDAr-mediated. “The data from these studies demonstrate that NYX-2925 is biologically active in the human brain,” said Norbert Riedel, Ph.D., president and CEO of Aptinyx.